Merck Isentress Gets Advisory Panel Support But May Get Narrow Indication
Executive Summary
Although divided on whether the indication for Merck's Isentress (raltegravir) should be narrowed, FDA's Antiviral Drugs Advisory Committee voted unanimously in favor of accelerated approval for the HIV drug on Sept. 5